Biological drugs are gradually becoming the treatment of choice for chronic autoimmune diseases. However, their high costs are a key healthcare concern limiting their attractiveness for payers. This can, in part, be offset by implementing drug response biomarkers so that payers will only cover the drugs for patients who are most likely to benefit from them. Identifying such biomarkers in turn depends on the availability of well-characterized clinical samples. Research collaboration between the pharmaceutical industry, clinicians, and academia is paramount for achieving this goal.
- autoimmune diseases
- biological drugs
- clinical trials
- data sharing
- genome-wide expression profiling